Cyclin K plays a critical role in transcriptional regulation as well as cell development. However, the role of Cyclin K in prostate cancer is unknown. Here, we describe the impact of Cyclin K on prostate cancer cells and examine the clinical relevance of Cyclin K as a biomarker for patients with prostate cancer. We show that Cyclin K depletion in prostate cancer cells induces apoptosis and inhibits proliferation accompanied by an accumulation of cells in the G2/M phase. Moreover, knockdown of Cyclin K causes mitotic catastrophe displayed by multinucleation and spindle multipolarity. Furthermore, we demonstrate a Cyclin K dependent regulation of the mitotic kinase Aurora B and provide evidence for an Aurora B dependent induction of mitotic catastrophe. In addition, we show that Cyclin K expression is associated with poor biochemical recurrence-free survival in patients with prostate cancer treated with an adjuvant therapy. In conclusion, targeting Cyclin K represents a novel, promising anti-cancer strategy to induce cell cycle arrest and apoptotic cell death through induction of mitotic catastrophe in prostate cancer cells. Moreover, our results indicate that Cyclin K is a putative predictive biomarker for clinical outcome and therapy response for patients with prostate cancer.
Prostate cancer is the most commonly diagnosed solid cancer in men and one of the leading causes of cancer-related deaths. Therapeutic options for prostate cancer include surveillance, radical prostatectomy, radiation, hormone therapy and chemotherapy. 1 However, periods of remission are often followed by a recurrence of the cancer. 2, 3 Despite the increasing number of biomarker studies, better prognostic and predictive markers for prostate cancer are still urgently needed. 4 In prostate cancer, like in many other cancer types, dysregulation of the cell cycle resulting in uncontrolled proliferation is one of the major tumour features. Based on this, the expression of 31 cell cycle progression genes has been described as a novel prognostic marker in patients with prostate cancer. 5 However, although cyclins play an important role in cell cycle regulation and proliferation, little is known about their role in prostate cancer. Previous studies have shown that Cyclin D1 overexpression is implicated in prostate cancer tumorigenesis and aggressive tumour progression. 6, 7 Moreover, Cyclin A expression is increased in prostate cancer and this is associated with poor survival of the patients. 8 In addition, it has been demonstrated that the negative cell cycle regulator Cyclin G2 exhibits a lower expression in prostate cancer compared to normal tissue and that this correlates with clinical and pathological parameters.
Recently, Xiang et al. showed a high expression of Cyclin K (CycK) in testicular tumours and a crucial role for CycK in the proliferation of testicular cancer cells. 10 Moreover, the functional importance of CycK is indicated by the observation that genetically inactivated CycK causes early embryonic lethality in mice. 11 In addition, an involvement in transcription has been attributed to CycK. CycK was identified as a binding partner of RNA polymerase II in 1998 by Edwards et al. 12 and several studies have demonstrated that CycK is a regulatory subunit of CDK12 and CDK13. 11, 13 Although genomic alterations of CDK12 have recurrently been identified in prostate cancer, [14] [15] [16] studies on the functional role of CycK in cancer are still lacking and in particular, the importance of CycK in prostate cancer is unknown.
In this study, we explore the mechanisms of CycK dependent regulation of proliferation and apoptosis in prostate cancer. We demonstrate that a reduction of CycK impairs cell growth and enhances apoptosis in prostate cancer cell lines through induction of mitotic catastrophe. Furthermore, we provide evidence that these effects are provoked by a decreased expression of the mitotic regulator Aurora B. In addition, we show that CycK expression correlates with therapy resistance in patients with prostate cancer. In this study we demonstrate for the first time the functional role of CycK in prostate cancer cells and its importance as a putative predictive marker in prostate cancer. 
Materials and Methods

Materials
Viability assay
For analysis of viability, prostate cancer cell lines were treated or transfected as described. At indicated time points, cells were washed with PBS, incubated with trypsin, harvested and cell number was determined using a Neubauer chamber.
Flow cytometry analysis
For analysis of cell cycle distribution, cells were subjected to a bromodeoxyuridine (BrdU) incorporation assay according to manufacturer's instruction (BD Bioscience, San Jose, CA, USA, 559619). Cells were subjected to flow cytometry analysis (FACS) using Becton Dickinson FACScalibur cytometer and Cell Quest Software (BD Bioscience). Apoptosis measurement was performed as follows: Cells were treated or transfected as indicated. Supernatant was collected, cells were washed with PBS, incubated with trypsin and harvested. Cells together with the supernatant were washed and stained with Annexin V-FITC (560931) and 7-AAD (559925) due to manufacturer's instructions (BD Bioscience). Cells were subjected to FACS analysis using Becton Dickinson FACScalibur cytometer and Cell Quest Software (BD Bioscience).
Immunoblot analysis
Immunoblot analysis was carried out as previously described. 19 What's new? Cell cycle progression genes represent a promising source for biomarker discovery in prostate cancer, though little is known about their role in the disease. This study shows in prostate cancer cells that depletion of Cyclin K, a cell cycle regulator, is associated with apoptosis and inhibition of proliferation. The effects of Cyclin K downregulation were linked to Cyclin K dependent and Aurora B-mediated induction of mitotic catastrophe. In patients treated with adjuvant therapy, Cyclin K expression was associated with reduced biochemical recurrence-free survival. The results warrant further investigation of Cyclin K as predictive biomarker in prostate cancer.
Expression microarray
For the expression microarray, DU-145 and PC-3 cells were transfected with CycK siRNAs and scram and RNA was isolated from the cells after 48 hrs and 96 hrs, as described previously. 19 Genome-wide mRNA expression was analysed using the Illumina BeadChip HumanHT-12 v4 following the manufacturer's instruction (Illumina, San Diego, CA, USA). The array was performed by the Genomics and Proteomics Core Facility at the German Cancer Research Center (DKFZ, Heidelberg, Germany). For each experimental setting, three biological replicates were prepared. Genes were considered differentially expressed when at least a 2-fold up-or downregulation was detected for both cell lines at either time point.
Quantitative real time PCR analysis
Quantitative real time PCR (RT-PCR) was performed as described previously. 19 Primer pairs were used as follows:
Immunofluorescence staining
For immunofluorescent staining, cells were seeded on coverslips and treated or transfected as described. At indicated time points, cells were rinsed with PBS and fixed with icecold methanol followed by ice-cold acetone. Cells were washed with ice-cold PBS and blocked with 10% goat serum (Vector, Burlingame, CA, USA, S-1000) in PBS. Subsequently, cells were incubated with a primary anti-b-tubulin antibody (1:200) and incubated over night at 48C. Cells were washed, counterstained with DAPI (0.1 mg/ml), rinsed with PBS and mounted using ProLong Gold Antifade Mountant (Thermo Fisher Scientfic, P10144).
Immunohistochemistry
For the immunohistochemical analysis of CycK in prostate cancer, a tissue microarray (TMA) of human prostate cancer was used. 
Statistical analysis
For statistical analyses the unpaired 2-sided Student's t test was used to calculate significant differences. Statistical analyses for the TMA were performed using SPSS 22.0 (IBM, Armonk, NY, USA): Univariate analyses were performed using a two-sided Pearson v 2 test. The Kaplan-Meier method was applied to calculate the probabilities for biochemical recurrence (BCR)-free survival. The Cox proportional hazards regression was used for uni-and multivariate analyses for BCR-free survival. P < 0.05 was considered significant.
Results
CycK regulates apoptosis, proliferation and cell cycle distribution in prostate cancer cells
In order to elucidate the relevance of CycK in tumour cells, endogenous CycK expression was analysed in the three prostate cancer cell lines DU-145, LNCaP and PC-3 (Fig. 1a) . All cell lines examined demonstrated CycK expression. For functional characterization, CycK expression was downregulated using two small interfering RNAs (siRNAs) targeting CycK (CycK si-1, CycK si-2) (Fig. 1b) . Upon CycK silencing all cell lines showed a considerable decrease in viability, displayed by a significant reduction in cell number (Fig. 1c) . Furthermore, we investigated whether this reduction was caused by induction of apoptosis. CycK silencing induced apoptosis in DU-145 cells, accompanied by increased cleavage of Caspase-3 (Fig. 1d,e) . In contrast, in LNCaP and PC-3 cells no induction of apoptosis was detected. Consequently, we were interested in the events leading to decreased viability in LNCaP and PC-3 cells. Therefore, cell cycle analysis was performed to investigate the effect of CycK siRNA on cell cycle phase distribution. Consistent with findings by Blazek et al. 11 CycK depletion resulted in a significant accumulation of cells in the G2/M phase of the cell cycle in all cell lines, pointing to an inhibition of proliferation (Fig. 1f) .
CycK depletion provokes mitotic catastrophe
To further address the effects of CycK knockdown on the cell cycle and especially mitosis, we performed immunofluorescent stainings of prostate cancer cells. We observed that CycK depletion promotes the formation of giant multinucleated cells in PC-3 cells and the arrangement of abnormal and multiple spindle poles in DU-145 and PC-3 cells (Fig. 2a-2d ). These mitotic defects are usually considered to be associated with mitotic catastrophe and consequently apoptotic cell death or growth arrest. 20 To examine whether mitotic catastrophe is caused by a defective function of either CycK-associated kinase CDK12 or CDK13, we reduced their expression using siRNAs targeting CDK12 and CDK13, respectively (Supporting Information Fig. S1A ). Simultaneous knockdown of CDK12 and CDK13 led to enlarged and multinucleated PC-3 cells and resulted in spindle multipolarity in DU-145 and PC-3 cells, similar to CycK reduction (Supporting Information Fig. S1B-D) . Likewise, an induction of mitotic catastrophe could not be observed in LNCaP cells. Transfection of either CDK12 siRNA or CDK13 siRNA alone triggered mitotic catastrophe only to a slight extent in DU-145 and PC-3 cells. To determine whether the effects mediated by CycK depletion are a consequence of mitotic catastrophe, we analysed the initiation of mitotic catastrophe employing the pharmacological triggers docetaxel 21 and griseofulvin, 22 respectively. Interestingly, induction of mitotic catastrophe in prostate cancer cells substantially diminished viability in all cell lines examined (Fig. 2e) . Notably, analogous to CycK knockdown, mitotic catastrophe triggered by griseofulvin treatment elevated apoptosis rate in DU-145 cells, but not in LNCaP and PC-3 cells (Fig. 1f) . Moreover, treatment of the prostate cancer cells with docetaxel demonstrated a higher sensitivity of DU-145 cells towards apoptosis induction compared to LNCaP and PC-3 cells (Fig. 1f) . In addition, in all cell lines treatment with docetaxel and griseofulvin caused mitotic catastrophe, displayed by multiple spindle pole formation or multinucleation (Supporting Information Fig. S2 ). Thus, these results demonstrate that CycK regulates proliferation and apoptosis in prostate cancer cells by triggering mitotic catastrophe.
Effects of CycK depletion are mediated by decreased expression of Aurora B
To determine the molecular mechanisms of CycK-mediated regulation of proliferation and apoptosis, an Illumina based expression profiling mRNA array was performed after CycK silencing. To confirm differentially expressed genes predicted by the microarray, RT-PCR was carried out with the selected down-or upregulated genes (data not shown). In addition, immunoblot analyses verified expression alterations at the protein level (data not shown). Interestingly, depletion of CycK resulted in significantly lower mRNA and protein levels of Aurora B (Fig. 3a,b) which was accompanied by decreased phosphorylation of histone H3, a direct downstream target of Aurora B, 23 in DU-145 and PC-3 cells (Fig. 3c) . Next, we examined whether diminished Aurora B expression levels provoked by downregulation of CycK are caused by an impaired function of either CDK12 or CDK13. Therefore, expression of both kinases was reduced using siRNAs and levels of Aurora B mRNA were analysed. Knockdown of CDK12 led to a significant decrease of Aurora B mRNA expression in DU-145 cells, whereas its levels remained unaffected by CDK13 siRNA in DU-145, LNCaP and PC-3 cells (Fig. 3d) . Interestingly, a simultaneous knockdown of both CycK-associated kinases significantly reduced Aurora B mRNA expression in all prostate cancer cell lines (Fig. 3d) . Of note, Aurora B is a critical mitotic regulator required for chromosome condensation, chromatid separation, the spindle assembly checkpoint and cytokinesis during the cell cycle. 24, 25 It has further been shown, that inhibition of Aurora B leads to impaired cell cycle progression and incomplete mitosis, resulting in growth arrest, multinucleation and polyploidy of cells, [24] [25] [26] similar to CycK depletion. To examine whether the effects caused by CycK siRNAs are mediated through repression of Aurora B expression, we reduced Aurora B levels by a siRNA targeting Aurora B (AURKB si) and a control siRNA (scram) (Fig. 4a) . Downregulation of Aurora B caused a substantial decrease in cell viability in all cell lines examined (Fig. 4b) . Furthermore, the apoptosis rate was remarkably elevated in DU-145 cells (Fig. 4c,d) . Moreover, analysis of cell cycle distribution demonstrated an accumulation of cells in the G2/M phase of the cell cycle (Fig. 4e) . Knockdown of Aurora B further induced multinucleation and spindle apparatus defects in the prostate cancer cells (Supporting Information Fig. S3A-C) . Compared to DU-145 and PC-3 cells, LNCaP cells demonstrated a substantial lower percentage of multinucleated cells upon Aurora B siRNA indicating a reduced susceptibility towards induction of mitotic catastrophe (Supporting Information Fig. S3D ). Taken together, the impact of Aurora B silencing on proliferation, apoptosis and cell cycle in prostate cancer is similar to the effects provoked by CycK depletion.
CycK is an independent predictive marker for therapy resistance in prostate cancer
To determine the clinical relevance of CycK, the expression of CycK was immunohistochemically evaluated in prostate cancer samples using a TMA. Since we were interested whether CycK can be used as a predictive biomarker for therapy resistance, we evaluated CycK expression in 91 patients of the TMA collective, who received adjuvant therapy. Supporting Information Table S1 provides a summary of the clinical and pathological features of these patients. CycK expression levels showed a substantial variability in prostate cancer tissue samples (Fig. 5a ). We analysed the association of CycK expression and clinicopathological characteristics (Supporting Information Table  S2 ). Notably, patients characterized by low CycK expression levels showed a good prognosis with regard to biochemical recurrence (BCR; p 5 0.020) (Fig. 5b) and surgical margin status (p 5 0.027), compared to patients with a high CycK expression. Consistently, Kaplan-Meier analysis revealed that the BCR-free survival was significantly shorter in patients with high CycK expression levels in contrast to patients with low CycK expression ( Fig. 5c ; log-rank, p 5 0.004).
For further validation, we investigated the effect of CycK expression on the BCR-free survival by uni-and multivariate Cox regression analysis. Therefore, the association of CycK expression, Gleason score, pT, pN, M and margin status with BCR-free survival was analysed (Table 1 ). In the univariate analysis, but not in the multivariate analysis, pN was predictive for BCR-free survival (p 5 0.016). CycK expression emerged as an independent predictive marker for BCR-free survival in the univariate (p 5 0.004) and multivariate analysis (p 5 0.018). In the multivariate analysis, apart from CycK expression, no clinicopathological marker analysed was a predictive marker for BCR-free survival in our cohort of men.
Discussion
The functional role of CycK in cancer is poorly understood. In the present study we demonstrate the importance of CycK in prostate cancer. We show that CycK depletion affects cells in an antitumourigenic manner by increasing apoptosis and decreasing proliferation accompanied by a G2/M arrest of the cell cycle. Consistent with these findings, it was previously reported that the reduction of CycK leads to a proliferation arrest in testicular cancer cells 10 and to an accumulation of cells in the G2/M cell cycle phase in cervical cancer cells. knockout is lethal in early embryogenic development. 11 These data support the evidence that CycK plays a key role in cell development. Of note, CycK has been described to associate with CDK12 and CDK13, respectively. 11, 13 Similar to CycK, the functional roles of CDK12 and CDK13 are not clear. However, it has been shown that CDK12 is also important for embryonic development and causes early lethality when knocked out. 27 Moreover, CDK12 depleted cervical cancer cells exhibit a G2/M cell cycle arrest similar to CycK silencing-mediated cell cycle deregulation. 11 Recently, Zhang et al. synthesized and described a novel compound THZ531, the first selective inhibitor for CDK12 and CDK13. 28 Interestingly, THZ531 exhibits strong anti-cancer activity in leukaemia cells through apoptosis induction and inhibition of proliferation. 28 Similarly, we observed that the simultaneous knockdown of CDK12 and CDK13 results in induction of mitotic catastrophe and decreased expression of Aurora B. This indicates that the effects provoked by CycK silencing are rather caused by a reduced activity of the CycK-CDK12/ 13 complex than by CycK alone. Moreover, these observations suggest a redundant function of both CDK12 and CDK13 within this context. In the present study, we show for the first time that CycK regulates Aurora B expression. Aurora B is part of the chromosomal passenger complex and is responsible for chromatid condensation, proper chromosome-kinetochore attachment, cytokinesis and the spindle assembly checkpoint. 24, 25 Therefore, Aurora B plays a critical role in the maintenance of accurate mitosis. In addition, Aurora B is frequently overexpressed in several cancers, including prostate cancer, and hence is considered an important target in cancer research. [29] [30] [31] [32] [33] The CycKAurora B association described in the present study demonstrates a novel regulative mechanism for Aurora B. The CycK dependent expression of Aurora B could be regulated directly through the CycK-CDK12/13 complex or indirectly through altered CycK-CDK12/13 mediated phosphorylation of Aurora B [37] [38] [39] We demonstrate an induction of mitotic catastrophe upon knockdown of CycK and Aurora B. In agreement with these results, Aurora B depletion has been shown to induce mitotic catastrophe. 26, 40 Since lack of Aurora B results in cytokinesis failure, cells display spindle multipolarity and multinucleation. 41, 42 Therefore, it appears that mitotic catastrophe induced by CycK depletion is provoked by a reduced expression of Aurora B. Interestingly, when using a different trigger for mitotic catastrophe (CycK siRNA, AURKB siRNA, docetaxel, griseofulvin), a similar phenotype is detected depending on the cell line: Potent induction of apoptosis in DU-145 cells and strong or moderate apoptosis resistance in LNCaP and PC-3 cells. The observation, that mitotic catastrophe induced by different triggers affects apoptosis and proliferation in prostate cancer cells in the same way, corroborates the hypothesis that the effects upon CycK knockdown are caused by mitotic catastrophe induction. Although the effects mediated by downregulation of CycK are most likely provoked by a CycK dependent regulation of Aurora B, stable overexpression of Aurora B is not able to rescue the reduction observed in the cell number in PC-3 cells caused by CycK siRNAs (data not shown). However, it has been described that overexpression of Aurora B results in genomic instability because of defective cell cycle progression and uncontrolled mitosis. 43 Therefore, a successful rescue of the effects provoked by CycK knockdown by an overexpression of Aurora B might not be possible. However, Aurora B might be only one of several proteins regulated by CycK that play a role in this context. Interestingly, we observed different effects mediated by CycK downregulation in different cell lines used in the present study. LNCaP cells show the most potent resistance to CycK silencing compared to DU-145 and PC-3 cells. However, the three cell lines vary considerably in their genomic profile. Based on this, LNCaP cells, in contrast to DU-145 and PC-3 cells, are androgen sensitive and express a wild type p53 protein. 44 Interestingly, wild type p53 has been demonstrated to reduce multinucleation in response to Aurora B inhibition. 40 This points to an involvement of p53 mutation status on induction of mitotic catastrophe upon CycK knockdown in prostate cancer cells. Moreover, LNCaP and PC-3 cells harbour a mutated PTEN gene, whereas DU-145 cells express wildtype PTEN. 45 The impact of these genetic differences on the effects caused by CycK silencing remains to be elucidated.
To address the clinical relevance of CycK regarding its potential use as a predictive biomarker, an analysis of CycK expression in 91 prostate cancer patients who underwent radical prostatectomy followed by adjuvant therapy was carried out. This analysis identified CycK as a biomarker for predicting therapy response in prostate cancer patients. Interestingly, in the analysed prostate cancer patient collective, CycK is the only independent predictive marker for BCR-free survival whereas the clinical features Gleason score, pT, pN, M and margin status show no predictive significance. This could be due to the rather homogenous patient collective which included mainly locally advanced high grade prostate carcinoma but no indolent tumours, resulting in a small variance in the patient cohort. This is indicated by the fact that no well-differentiated Gleason scores ( 6) were represented in the cohort and that almost all tumours were staged either pT3, pT4, pN1 or R1. Further studies on CycK expression in association with clinicopathological markers and clinical outcomes are required. However, the results from this study are in accordance with previous studies, which show that CycK is highly expressed in testicular tumours compared to noncancerous cells and co-localizes with Ki67, a proliferation marker. 10 Interestingly, the binding partners of CycK, CDK12 and CDK13, have been reported to be highly overexpressed genetically in several tumour entities. 46, 47 Furthermore, low levels of CDK12 in ovarian cancer patients, who receive platinum therapy, show improved survival compared to patients with high CDK12 levels. 48 These observations lead to the question why patients with low CycK expression benefit more from an antitumor therapy. Based on the results from the present study, cellular proliferation in tumours lacking CycK is impaired and mitotic defects are more present compared to tumours with high CycK levels. Interestingly, enhancing mitotic damage in cancer cells has been shown to be a therapeutic strategy. 49 It has been demonstrated that Barasertib (AZD1152), a selective Aurora B inhibitor, induces mitotic catastrophe and sensitizes cancer cells for radiation therapy. 26, 50 Similarly, in the present study we show that tumours with low CycK are more susceptible to adjuvant radiation and hormone therapy. This is indicated by a better prognosis of patients with low CycK expression with regard to BCR-free survival compared to patients with high CycK expression (Fig. 5c) . A possible promising therapy approach for high CycK expressing tumours could be a combination therapy with the Aurora B inhibitor Barasertib with radiation and/or hormone therapy, respectively. In addition, the novel covalent CDK12/CDK13 inhibitor THZ531 might allow new approaches for the therapy of high CycK prostate cancer. In particular, tumours expressing high levels of CycK could benefit from an Aurora B or CDK12/CDK13 targeting therapy in combination with radiation or hormone therapy.
Our study demonstrates that CycK is an attractive target for cancer research. We show the potent anti-cancer activity of CycK downregulation through induction of mitotic catastrophe and identify CycK as predictive biomarker for patients with prostate cancer.
